Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. Compounded GLP-1 medications discussed in this review are prescription medications prepared by licensed compounding pharmacies and are not FDA-approved finished drugs. Nothing in this article constitutes medical advice. Consult a licensed healthcare provider before starting any prescription medication.
Oak Longevity, operated under the consumer-facing domain oaklovesyou.com, is a telehealth platform offering compounded GLP-1 medications for weight management. The platform's headline pricing — compounded semaglutide from $130 per month and compounded tirzepatide from $199 per month, with no membership fee — is meaningfully lower than the dominant compounded-GLP-1 telehealth providers in the category. That pricing is the question this review answers: is it real, what does it actually include, and where do the costs sit relative to the competitors most readers compare it against?
Our editorial team analyzed Oak Longevity's published platform information, compared its pricing structure against three direct competitors (Mochi Health, Hims, and the on-domain reviewed SynergyRx GLP-1 program), and traced the compounded-vs-FDA-approved distinction back to the regulatory framework that governs both. We don't write reviews from press releases. We write to verifiable facts.
What Oak Longevity Actually Is
Oak Longevity is a direct-to-consumer telehealth platform. Patients complete an online health questionnaire, a licensed provider reviews the submission, and — if the provider determines treatment is clinically appropriate — a prescription for compounded semaglutide or compounded tirzepatide is dispensed through a licensed U.S. compounding pharmacy and shipped to the patient's home. There is no in-person clinic visit. There is no scheduled video consultation requirement, based on Oak's published intake description.
The platform's positioning emphasizes three things: affordability versus brand-name GLP-1 medications, the absence of monthly membership fees that other compounded-GLP-1 telehealth providers charge, and a streamlined intake process. Oak states that the program includes free shipping and access to free health coaching as standard features rather than upgraded tiers.
It is important to be precise about what Oak prescribes. Compounded semaglutide and compounded tirzepatide contain the same active pharmaceutical ingredients as the FDA-approved brand-name medications (Wegovy, Ozempic, Mounjaro, Zepbound), but they are not the same finished products. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions. They are not reviewed or approved by the FDA as finished drugs. The FDA has issued guidance addressing compounded GLP-1 products specifically, and consumers evaluating any compounded-GLP-1 telehealth provider — Oak, its competitors, or anyone else — should understand the regulatory distinction.
Oak's Published Pricing — Audited
Oak's published starting prices are straightforward: compounded semaglutide from $130 per month, compounded tirzepatide from $199 per month, with $50 off the first month using promotional code OAKNEW50. The platform advertises no membership fees, no subscription requirements, free shipping, and free health coaching. On its own homepage, Oak presents a competitor comparison table positioning brand-name GLP-1 medications at $1,000 to $1,400 per month and other telehealth platforms at $400 to $500 per month with $50 to $99 monthly membership fees.
Reading the headline price as the total monthly out-of-pocket cost requires one important caveat. GLP-1 medications are titrated — the dose is gradually increased from a starting low dose to a clinically effective maintenance dose over a period of weeks to months. Across the compounded-GLP-1 telehealth category, dose-specific pricing varies. Patients on Oak's platform should confirm with the consultation whether the $130 starting price applies at every titration step or whether the price scales with the prescribed dose. This is a question worth asking on every compounded-GLP-1 telehealth platform, including Mochi, Hims, Ro, and the platforms we have previously reviewed on this domain.
For comparison context: on competing platforms, Mochi Health charges a $79 per month membership plus $99 per month for compounded semaglutide at all standard doses, for a total of $178 per month — meaningfully higher than Oak's $130 starting price even on a flat-dose basis. Hims uses multi-month prepaid plans starting around $199 per month for semaglutide-only with a six-month prepayment commitment. The on-domain SynergyRx review shows compounded semaglutide injection starting at $199 per month. Within the compounded-GLP-1 telehealth category, Oak's $130 starting price is at the low end of the published market rate. Whether that translates to the lowest total monthly cost depends on the specific dose and the duration of treatment — variables that are patient-specific and not platform-specific.
How GLP-1 Medications Work
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management. They work by mimicking the action of the naturally-occurring GLP-1 hormone, which is released after eating and helps regulate appetite, gastric emptying, and insulin secretion. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual receptor agonist, acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
Peer-reviewed clinical trial data has established the weight-management role of these medications in eligible patients. The STEP program studied semaglutide; the SURMOUNT program studied tirzepatide. Both demonstrated meaningful average weight reduction over 6 to 12 months in adults meeting clinical eligibility criteria, when combined with structured nutrition and physical activity guidance and under medical supervision. Individual results vary substantially based on baseline weight, adherence, comorbidities, and lifestyle factors. The peer-reviewed evidence base applies specifically to the FDA-approved formulations studied in those trials. Compounded versions of the same active ingredients have not been studied in the same head-to-head trial framework, which is a real and relevant distinction.
Eligibility — What Oak Says, What Providers Decide
Oak's published eligibility framework states that the platform is not appropriate for adults under 18, individuals who are pregnant or nursing, or individuals with BMI under 22 with no comorbidities. Beyond those exclusions, the platform's eligibility model defers to the licensed clinician who reviews the intake — meaning the provider determines clinical appropriateness based on the patient's specific health information, not a fixed BMI threshold.
This is consistent with how compounded-GLP-1 telehealth platforms across the category operate. The standard eligibility benchmark in obesity medicine is a body mass index of 30 or higher, or 27 or higher with at least one weight-related comorbid condition. Patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or certain pancreatic conditions are not appropriate candidates regardless of BMI. Patients with these histories should disclose them in the intake, and a thorough intake review should screen for them. The clinical decision to prescribe — or not — belongs to the licensed provider.
The Intake Process
Oak's intake follows the now-standard compounded-GLP-1 telehealth pattern: an online health questionnaire collecting medical history, current medications, weight history, and lifestyle information; a licensed provider review of the submission; and, if approved, a prescription dispensed through a licensed compounding pharmacy partner with home delivery. Oak states the platform offers free health coaching alongside the medication, and ongoing support is available through the platform's care team.
One distinction worth flagging: Oak's published process emphasizes a no-video-call intake. Some compounded-GLP-1 telehealth platforms — Mochi being the clearest example — require or strongly emphasize live video visits as part of the intake and ongoing care. Asynchronous intake is faster and more convenient. Live video intake provides a richer clinical evaluation. Neither is universally better; the right choice depends on the patient's preference and clinical complexity. Patients with multiple comorbidities, medication interactions, or complex weight histories may benefit more from platforms that include live clinical interaction.
What the Trustpilot Reviews Show
Oak Longevity's Trustpilot profile shows a 4-star aggregate rating across 46 reviews as of our review check date. That sample size is small relative to category leaders. Reviews skew positive on customer service responsiveness, ease of intake, and pricing satisfaction. One reviewer specifically noted that pricing escalated from $190 to $229 across titration steps on a real account — useful real-world detail relative to the platform's “one price all dosages” marketing language. This is not a contradiction so much as a clarification: Oak's published starting prices are accurate; what the patient ultimately pays depends on the prescribed dose, as it does on every compounded-GLP-1 telehealth platform.
One Trustpilot reviewer also noted that Oak does not currently offer prescription anti-nausea medications alongside the GLP-1 prescription. Nausea is the most common side effect of GLP-1 initiation and titration, and some platforms include ondansetron access as part of the protocol when clinically appropriate. Patients prone to nausea may want to confirm whether Oak provides supportive medication access through its consultation.
Side Effects and Safety
The side effect profile of compounded semaglutide and compounded tirzepatide reflects the side effect profile of the active ingredients. Common side effects, particularly during initiation and dose escalation, include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These typically improve as the body adjusts to the medication or as the provider adjusts the titration schedule. Less common but more serious risks include pancreatitis, gallbladder issues, and — in rare cases with the FDA-approved labeled medications — thyroid C-cell tumors observed in animal studies. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use these medications.
Compounded-GLP-1-specific safety considerations: because compounded medications are not FDA-approved finished drugs, the active ingredient sourcing, sterility, and dosing accuracy depend on the specific compounding pharmacy. Oak states that prescriptions are dispensed through licensed U.S. compounding pharmacies. The FDA has previously addressed safety concerns related to specific compounded-GLP-1 products, particularly those using salt forms of semaglutide rather than the base molecule. Patients should be able to ask the platform — Oak or any competitor — about the specific active pharmaceutical ingredient form being dispensed.
Pros, Cons, and the Honest Read
The honest read on Oak Longevity, after the pricing audit and the platform-mechanics review: at $130 per month starting price for compounded semaglutide with no membership fee, Oak's published pricing is at the low end of the compounded-GLP-1 telehealth category. The asynchronous intake is faster than video-required platforms, which is a genuine convenience benefit and a genuine clinical depth tradeoff. The compounded-only formulary means patients seeking FDA-approved brand-name medications need a different platform.
The cons that apply to Oak apply to the compounded-GLP-1 telehealth category broadly: compounded medications are not FDA-approved finished products, the regulatory environment is evolving, and the dose-specific pricing patients ultimately pay depends on titration. Oak's specific limitations relative to some competitors include a smaller Trustpilot review base, no published prescription anti-nausea support, and a no-video-call intake that suits some patients better than others.
For patients who prioritize the lowest published starting price on a no-membership-fee structure and whose clinical situation is well-suited to asynchronous intake: Oak's pricing position is real and competitive. For patients who want richer ongoing clinical interaction, FDA-approved brand-name access, or extensive third-party-validated review history: other platforms in the category will fit better. For a side-by-side breakdown against the closest-priced competitors, see our companion Oak vs Mochi vs Hims comparison.
How to Get Started
Patients begin at oaklovesyou.com, complete the online health questionnaire, and — if approved by the licensed Oak provider — receive their prescription via licensed compounding pharmacy delivery. Oak states that the intake process takes minutes and approval can occur within hours. The promotional code OAKNEW50 applies $50 off the first month per the platform's published offer.
Before starting any compounded-GLP-1 program, patients should review the full eligibility framework with their healthcare provider, disclose all relevant medical history including thyroid and pancreatic history, and understand that compounded medications are prepared individually by licensed pharmacies and are not FDA-approved finished drugs. The clinical decision to start, continue, or discontinue GLP-1 therapy belongs to the patient and a qualified medical professional, not to a marketing comparison.
Final Editorial Take
Oak Longevity's pricing claim holds up to audit on its starting numbers. Compounded semaglutide at $130 per month with no membership fee is meaningfully cheaper than Mochi's $178 per month total, Hims' $199 per month with prepayment commitments, or the SynergyRx $199 per month starting price we covered in our SynergyRx review. The “lowest total cost” question for any specific patient depends on the prescribed dose, the duration of treatment, and how dose-specific pricing scales — a question patients should ask directly during the consultation rather than infer from marketing pages.
Oak's compounded-only formulary, asynchronous intake, and absence of prescription anti-nausea support are real limitations relative to some competitors. Its low entry price and clean no-membership-fee structure are real advantages. The platform sits where its marketing positions it — at the affordable end of the compounded-GLP-1 telehealth category — without the extreme overstatement that would invite scrutiny. For category context and additional analysis, see our broader coverage in the Telehealth Platform Reviews and Weight Management sections, and the deeper cost analysis in Compounded Semaglutide Cost: What $130/Month Means.
Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs. Some links may be affiliate links; full details in the site's affiliate disclosure. Pricing referenced reflects Oak Longevity's published rates as of the review date and is subject to change.